Piramal Pharma has awarded its built-in media mandate to OMD India, a part of Omnicom Media Group. Following a multi-round pitch, the company has been chosen to deal with the model’s development by means of inventive and efficient communication.
OMD India will spearhead the strategic advertising and marketing and media efforts for Piramal Pharma’s portfolio of OTC manufacturers, together with Lacto Calamine, Little’s, Tetmosol, Polycrol, and Ladies’s intimate well being vary like i-pill and i-activ, and will likely be managed out of the company’s Mumbai workplace.
OMD will deal with bettering Piramal Pharma’s market presence, model consciousness, client engagement, and advertising and marketing technique to drive enterprise development.
“We’re excited to embark on this partnership with Piramal Client Healthcare, an organization that mirrors our dedication to innovation and excellence,” mentioned Anisha Iyer, CEO of OMD India. “This collaboration presents a big alternative to leverage our strategic acumen and deep market intelligence to raise Piramal’s spectacular portfolio of manufacturers to new heights. Collectively, we intention to craft media methods that transcend visibility—constructing lasting belief and loyalty with customers throughout India and shaping a way forward for sustained development and influence.”
Written with the View : afaqs
